The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be ...
This model illustrates how SETD1B promotes the expansion of H3K4me3 epigenetic marks and upregulates MYC expression, driving cytokine-independent cell growth in FLT3-mutated AML. Acute myeloid ...
- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML - - Findings from the Phase 3 ...
Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibody Use in Earlier Lines of Treatment of Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma Anthracycline and cytarabine ...
Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...
A novel mouse model of a highly lethal form of acute myeloid leukemia (AML) offers a new tool for scientists working to better understand this disease and research new therapeutic targets. Scientists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results